| Patient no. | Age/Sex | Underlying disease | Prophylactic antimicrobials (0 ral) | BDG level (pg/ml) | GM index | Empirical antibiotics (Drip Infusion) | L-Am B Dose (Duration) | Adverse events | Outcome |
| 1 | 65/F | Acute leukemia | FLCZ | Negative | Negative | Meropenem + Linezolid | 120 mg (7 days) | Nothing | Success |
| 2 | 78/M | Acute leukemia | LVFX + FLCZ | Negative | Negative | Doripenem → Meropenem | 150 mg (22 days) | Nothing | Success |
| 3 | 69/M | Acute leukemia | VRCZ | Negative | Negative | Meropenem + Vancomycin | 135 mg (11 days) | K3.2 mEq/L (G2) | Success |
| 4 | 50/M | Acute leukemia | NA | Negative | Negative | Doripenem + Arebekacin | 150 mg (12 days) | GPT 49 IU/L (G1) | Success |
| 5 | 67/F | Acute leukemia | ST + ITCZ | Negative | Negative | Meropenem + Arbekacn | 112 mg (10 days) | GPT 53 IU/L (G1) | Success |
| 6 | 42/M | Acute leukemia | FLCZ | Negative | Negative | Meropenem + Vancomycin | 185 mg (11 days) | Nothing | Success |
| 7 | 43/M | Acute leukemia | LVFX + FLCZ | 84.2 | Negative | Meropenem | 200 mg (11 days) | Anal pain (G2) | Success |
| 8 | 70/F | Acute leukemia | FLCZ | Negative | Negative | Imipenem + Vancomycin | 150 mg (11 days) | Creatinine 1.0 mg/dL (G1) | Success |
| 9 | 64/M | Non-Hodgkin lymphoma | LVFX + ST + ITCZ | 43.4 | NA | NA | 150 mg (8 days) | Physical rigidity (G2) | Failure |
| 10 | 66/M | Myelodysplastic syndrome | ST | Negative | Negative | Doripenem + Vancomycin | 100 mg (3 days) 50 mg (3 days) | Creatinine 2.3 mg/dL (G2) | Failure |
| 11 | 75/M | Acute leukemia | FLCZ | Negative | Negative | Cefepime + Vancomycin | 125 mg (16 days) | GPT 75 IU/L (G1), K 2.2 m Eq/L (G2) | Failure |